N-arachidonoyl vanillylamine

N-arachidonoyl vanillylamine is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 166 references associated with N-arachidonoyl vanillylamine in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.

Here are additional resources we collected from PubChem and MeSH for N-arachidonoyl vanillylamine

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with N-arachidonoyl vanillylamine

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Hypertension D006973 115 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Hyperkinesis D006948 11 associated lipids
Respiration Disorders D012120 5 associated lipids
Total 5

NCBI Entrez Crosslinks

All references with N-arachidonoyl vanillylamine

Download all related citations
Per page 10 20 50 | Total 33
Authors Title Published Journal PubMed Link
Hurley JD et al. Non-pungent long chain capsaicin-analogs arvanil and olvanil display better anti-invasive activity than capsaicin in human small cell lung cancers. 2017 Cell Adh Migr pmid:27196129
Barrière DA et al. Fatty acid amide hydrolase-dependent generation of antinociceptive drug metabolites acting on TRPV1 in the brain. 2013 PLoS ONE pmid:23940628
Stock K et al. Neural precursor cells induce cell death of high-grade astrocytomas through stimulation of TRPV1. 2012 Nat. Med. pmid:22820645
Kopczyńska B Midcervical vagotomy precludes respiratory response to novel anti-inflammatory and anti-tumour drug arvanil in rats. 2010 Eur. J. Pharmacol. pmid:20599930
Ursu D et al. Pungency of TRPV1 agonists is directly correlated with kinetics of receptor activation and lipophilicity. 2010 Eur. J. Pharmacol. pmid:20576527
Kopczyńska B Role of VR1 and CB1 receptors in modelling of cardio-respiratory response to arvanil, an endocannabinoid and vanilloid hybrid, in rats. 2008 Life Sci. pmid:18572197
Qin N et al. TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. 2008 J. Neurosci. pmid:18550765
Sharkey KA et al. Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. 2007 Eur. J. Neurosci. pmid:17459108
Malfitano AM et al. Arvanil and anandamide up-regulate CD36 expression in human peripheral blood mononuclear cells. 2007 Immunol. Lett. pmid:17360047
Márquez N et al. Iodinated N-acylvanillamines: potential "multiple-target" anti-inflammatory agents acting via the inhibition of t-cell activation and antagonism at vanilloid TRPV1 channels. 2006 Mol. Pharmacol. pmid:16394182